Drugging the undruggable – the story of Ras
Drug discovery and development are lengthy processes for even the most established Healthcare companies. Despite advancements in technology and ever more accessible research, commercialising new therapeutics still requires a significant amount of time and capital. Given these caveats, Healthcare companies dedicate significant resources to identify high potential drug targets within the cell. However, certain biomolecular components have proved challenging to build robust therapeutics for. Here, we explore why the Ras family of proteins are such attractive drug targets and why some Healthcare companies still have skin in the game despite four decades of failed attempts.
April 13, 2021
LUNAC Therapeutics: developing next-generation anticoagulant therapies
Anticoagulants are an essential class of medications that are primarily used to prevent thrombotic events in individuals classified as at high risk of blood clot formation. Several risk factors can increase an individual’s risk of developing a blood clot, including a previous history of blood clots (venous thromboembolism), a previous history of myocardial infarction or stroke, cardiac valve replacement, genetic clotting disorders and comorbidities such as atrial fibrillation.
Matthew McCann
March 11, 2021
What should founders think about in terms of law? An interview with Stephen Sykes - a lawyer and entrepreneur
In this interview, I talk with Stephen Sykes about what founders have to keep in mind, from a legal point of view, when starting their company. Stephen is a lawyer at The Sykes Partnership LLP who specialises in environmental law.
February 25, 2021
Can ageing be considered a disease?
Ageing is simply defined as ‘growing older’. ‘Growing older’ is something I believe many of us have accepted as our natural state, as all living things arise fresh, then age, weaken and finally die and that is largely considered as just the way things go. However, some believe ageing entails far more than just ‘growing older’, especially when looking from a health-focused perspective...
February 3, 2021
From Scientist to Scientist On Commercialising Scientific Research
The scale of venture innovation today is having a profound effect on many aspects of our lives, from our health, our productivity in our environment. Start-ups can have a positive impact on the economy and society but there is a risk that there will be a loss in costs due to ineffective product development, an ineffective team, negative externalities and the continuously changing technology landscape.
January 14, 2021
Zonova Animal Health: Combating the Antibiotic Resistance Crisis Using Bioengineering
The rising tide of antimicrobial resistance (AMR) is recognised as one of the major hurdles of the 21st century, being predicted to cause more deaths worldwide than cancer within the next 25 years [5]. Our overuse of antibiotic agents is driving the evolution of novel antimicrobial-resistant bacterial strains across both agricultural and healthcare sectors. Humanity is fighting a losing battle against billions of years of bacterial evolution. To keep in this fight, we need to come up with more innovative solutions within the field of antimicrobial biotechnology.
Aonghus Topham
Biostress: revolutionising workplace wellness through biometric innovation
Founded in 2020 by neuroscientist Tim Routledge and marketing leader Tim Wade, Biostress Lab Ltd set sail from Wakefield, England, with a mission to revolutionise workplace well-being.
Omar Ajaz